scholarly journals A dietary intervention to improve the microbiome composition of pregnant women with Crohn's disease and their offspring: The MELODY (Modulating Early Life Microbiome through Dietary Intervention in Pregnancy) trial design

2020 ◽  
Vol 18 ◽  
pp. 100573
Author(s):  
Inga Peter ◽  
Ana Maldonado-Contreras ◽  
Caroline Eisele ◽  
Christine Frisard ◽  
Shauna Simpson ◽  
...  
1997 ◽  
Vol 90 (2) ◽  
pp. 64-66 ◽  
Author(s):  
J Hill Chm ◽  
A Clark ◽  
Na Scott

When requiring surgery, acute exacerbations of Crohn's disease in pregnancy have been reported to carry high maternal and fetal mortality. We report six cases. The women presented at 30, 28, 12, 11, 31 and 25 weeks' gestation and all proved to have intraperitoneal sepsis. In three, the acute symptoms were the first indication of Crohn's disease. All the women recovered and five had healthy babies; the other had a miscarriage when a colonic anastomosis dehisced. In pregnant women with Crohn's disease, the indications for surgery are the same as in non-pregnant patients. For acute manifestations we recommend removal of the source of the sepsis and exteriorization of the bowel ends.


Author(s):  
Jurij Hanzel ◽  
Vipul Jairath ◽  
Peter De Cruz ◽  
Leonardo Guizzetti ◽  
Lisa M Shackelton ◽  
...  

Abstract Background The lack of standardized methods for clinical trial design and disease activity assessment has contributed to an absence of approved medical therapies for the prevention of postoperative Crohn’s disease (CD). We developed recommendations for regulatory trial design for this indication and for endoscopic assessment of postoperative CD activity. Methods An international panel of 19 gastroenterologists was assembled. Modified Research and Development/University of California Los Angeles methodology was used to rate the appropriateness of 196 statements using a 9-point Likert scale in 2 rounds of voting. Results were reviewed and discussed between rounds. Results Inclusion of patients with a history of completely resected ileocolonic CD in regulatory clinical trials for the prevention of postoperative recurrence was appropriate. Given the absence of approved medical therapies, a placebo-controlled design with a primary end point of endoscopic remission at 52 weeks was appropriate for drug development for this indication; however, there was uncertainty regarding the appropriateness of a coprimary end point of symptomatic and endoscopic remission and the use of currently available patient-reported outcome measures. The modified Rutgeerts Score, endoscopic assessment of the anastomosis, and a minimum of 5cm of neoterminal ileum were also appropriate; although the appropriateness of other indices including the Simple Endoscopic Score for CD for endoscopic assessment of postoperative CD activity was uncertain. Conclusions A framework for regulatory trial design for the prevention of postoperative CD recurrence and endoscopic assessment of disease activity has been developed. Research to empirically validate end points for these trials is needed.


2019 ◽  
Vol 25 (Supplement_1) ◽  
pp. S10-S10
Author(s):  
Kelli E DuBois ◽  
Michael Beets ◽  
Christine Blake ◽  
Jennifer McCabe

2020 ◽  
Vol 158 (6) ◽  
pp. S-21-S-22
Author(s):  
Roberta Caruso ◽  
Peter Kuffa ◽  
Naohiro Inohara ◽  
Gabriel Nunez

Nutrients ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3749
Author(s):  
David L. Suskind ◽  
Dale Lee ◽  
Young-Mo Kim ◽  
Ghassan Wahbeh ◽  
Namita Singh ◽  
...  

Background: Crohn’s disease (CD) is a chronic inflammatory intestinal disorder associated with intestinal dysbiosis. Diet modulates the intestinal microbiome and therefore has a therapeutic potential. The aim of this study is to determine the potential efficacy of three versions of the specific carbohydrate diet (SCD) in active Crohn’s Disease. Methods: 18 patients with mild/moderate CD (PCDAI 15–45) aged 7 to 18 years were enrolled. Patients were randomized to either SCD, modified SCD(MSCD) or whole foods (WF) diet. Patients were evaluated at baseline, 2, 4, 8 and 12 weeks. PCDAI, inflammatory labs and multi-omics evaluations were assessed. Results: Mean age was 14.3 ± 2.9 years. At week 12, all participants (n = 10) who completed the study achieved clinical remission. The C-reactive protein decreased from 1.3 ± 0.7 at enrollment to 0.9 ± 0.5 at 12 weeks in the SCD group. In the MSCD group, the CRP decreased from 1.6 ± 1.1 at enrollment to 0.7 ± 0.1 at 12 weeks. In the WF group, the CRP decreased from 3.9 ± 4.3 at enrollment to 1.6 ± 1.3 at 12 weeks. In addition, the microbiome composition shifted in all patients across the study period. While the nature of the changes was largely patient specific, the predicted metabolic mode of the organisms increasing and decreasing in activity was consistent across patients. Conclusions: This study emphasizes the impact of diet in CD. Each diet had a positive effect on symptoms and inflammatory burden; the more exclusionary diets were associated with a better resolution of inflammation.


2013 ◽  
Vol 7 (8) ◽  
pp. 678-679 ◽  
Author(s):  
Malini D. Sur ◽  
Anya M. Romanoff ◽  
Adrian J. Greenstein ◽  
Alexander J. Greenstein

2018 ◽  
Vol 154 (6) ◽  
pp. S-617-S-618
Author(s):  
Ariella Bar-Gil Shitrit ◽  
Ami Ben Yaacov ◽  
Dan M. Livovsky ◽  
Eran Goldin ◽  
Benjamin Koslowsky

2016 ◽  
Vol 151 (4) ◽  
pp. 724-732 ◽  
Author(s):  
Dalin Li ◽  
Jean-Paul Achkar ◽  
Talin Haritunians ◽  
Jonathan P. Jacobs ◽  
Ken Y. Hui ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document